Heavy Biologic, not really new competition as these type drugs are already in use for patients with severe UC.
If patients can be controlled with oral drugs they will not need something like this. Side effects can be an issue, also.
The US Food and Drug Administration (FDA) today approved a new indication for the tumor necrosis factor (TNF)-alpha inhibitor golimumab (Simponi, Janssen Biotech): treatment of adults with moderate to severe ulcerative colitis that is resistant to prior treatment or requires continuous steroid therapy.
Golimumab is also approved by the FDA for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis, and active ankylosing spondylitis.